이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cibus 관리

관리 기준 확인 1/4

Cibus' CEO는 Rory Riggs, Jan2001 에 임명되었습니다 의 임기는 23.42 년입니다. 총 연간 보상은 $ 292.31K, 100% 로 구성됩니다. 100% 급여 및 0% 보너스(회사 주식 및 옵션 포함). 는 $ 34.61M 가치에 해당하는 회사 주식의 14.06% 직접 소유합니다. 34.61M. 경영진과 이사회의 평균 재임 기간은 각각 1.1 년과 1 년입니다.

주요 정보

Rory Riggs

최고 경영자

US$292.3k

총 보상

CEO 급여 비율	100.0%
CEO 임기	23.7yrs
CEO 소유권	13.5%
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	1.3yrs

최근 관리 업데이트

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

Will Calyxt (NASDAQ:CLXT) Spend Its Cash Wisely?

Aug 17

CEO 보상 분석

Rory Riggs 의 보수는 Cibus 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$292m
Mar 31 2024	n/a	n/a	-US$286m
Dec 31 2023	US$292k	US$292k	-US$268m

보상 대 시장: Rory 의 총 보상 ($USD 292.31K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.62M ).

보상과 수익: Rory 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Rory Riggs (71 yo)

23.7yrs

테뉴어

US$292,314

보상

Mr. Rory Balfour Riggs, MBA, serves as Chief Executive Officer of Cibus, Ltd. since October 2021. He is Co-Founder at Cibus, Inc. and is its Chief Executive Officer and Chairman since June 1, 2023.Mr. Rig...

리더십 팀

이름	위치	테뉴어	보상	소유권
Rory Riggs	Co-Founder	23.7yrs	US$292.31k	13.53% $ 13.0m
Peter Beetham	Co-Founder	1.3yrs	US$292.31k	0.30% $ 284.7k
Greg Gocal	Co-Founder	8.7yrs	US$266.01k	0.25% $ 236.5k
Wade King	Chief Financial Officer	1.3yrs	데이터 없음	0.17% $ 159.4k
Jason Stokes	Chief Legal Officer	less than a year	데이터 없음	데이터 없음
Rosa Kim	Senior Vice President of Legal	no data	데이터 없음	데이터 없음
James Radtke	Senior Vice President of Product Development	no data	데이터 없음	데이터 없음
Tony Moran	Senior Vice President of International Development	no data	데이터 없음	데이터 없음
Norm Sissons	Senior Vice President of Seed & Traits	no data	데이터 없음	데이터 없음
Noel Sauer	Senior Vice President of Research	no data	데이터 없음	데이터 없음
Carlo Broos	Senior Vice President of Finance	less than a year	데이터 없음	데이터 없음
Sean O'Connor	Senior VP and President & CEO of Nucelis	no data	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: CBUS 의 관리팀은 경험 (평균 재직 기간 1.1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Rory Riggs	Co-Founder	1.3yrs	US$292.31k	13.53% $ 13.0m
Peter Beetham	Co-Founder	1.3yrs	US$292.31k	0.30% $ 284.7k
Gerhard Prante	Independent Vice Chairman	1.3yrs	데이터 없음	0.28% $ 269.7k
Mark Finn	Lead Independent Director	1.3yrs	데이터 없음	0.25% $ 245.0k
Keith Walker	Independent Director	1.3yrs	데이터 없음	0.33% $ 316.2k
Joseph Ecker	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jean-Pierre Lehmann	Independent Director	1.3yrs	데이터 없음	6.86% $ 6.6m
Jan Leach	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Stephen Howell	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Richard Meagher	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

78yo

평균 연령

경험이 풍부한 이사회: CBUS 의 이사회는 경험(평균 재직 기간 1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Cibus 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc., Annual General Meeting, May 30, 2024

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Cibus, Inc. Appoints Jim Collins to Board of Directors

Recent updates

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

New major risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022

Calyxt, Inc., Annual General Meeting, Jun 01, 2022

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Calyxt, Inc. to Report Q4, 2021 Results on Mar 03, 2022